

# Dave Dixon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1226100/publications.pdf>

Version: 2024-02-01

126  
papers

3,330  
citations

201385

27  
h-index

168136

53  
g-index

132  
all docs

132  
docs citations

132  
times ranked

4637  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Association of Altmetric Attention Scores With Citations in Selected Major Pharmacy Journals. <i>American Journal of Pharmaceutical Education</i> , 2022, 86, ajpe8606.	0.7	4
2	Predictors of job satisfaction among pharmacists: A regional workforce survey. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100124.	0.6	8
3	Survey of CDC-recognized community pharmacies providing the National Diabetes Prevention Program and impact of the COVID-19 pandemic on program delivery. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2022, 62, 1581-1586.	0.7	1
4	Midpoint of energy intake, non-fasting time and cardiorespiratory fitness in heart failure with preserved ejection fraction and obesity. <i>International Journal of Cardiology</i> , 2022, 355, 23-27.	0.8	4
5	Inclisiran: A knight in shining armor?. <i>American Heart Journal Plus</i> , 2022, 16, 100138.	0.3	0
6	Adherence to Lipid Monitoring and Its Impact on Treat Intensification of LDL-C Lowering Therapies at an Urban Academic Medical Center. <i>Journal of Clinical Lipidology</i> , 2022, , .	0.6	4
7	Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	8
8	Select drug-drug interactions with colchicine and cardiovascular medications: A review. <i>American Heart Journal</i> , 2022, 252, 42-50.	1.2	6
9	The Translational Approaches to Personalized Health Collaborative: Pharmacogenomics for African American Older Adults. <i>Clinical and Translational Science</i> , 2021, 14, 437-444.	1.5	2
10	Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis. <i>Current Therapeutic Research</i> , 2021, 95, 100635.	0.5	15
11	Identifying Training Needs and Active Information Opportunities in Primary Care Through the Analysis of Drug Information Requests. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002199697.	0.5	0
12	The student loan debt crisis is undermining our profession. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, 127-128.	0.7	0
13	Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1290-1299.	1.2	65
14	Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e69-e70.	1.4	30
15	Edema Index Predicts Cardiorespiratory Fitness in Patients With Heart Failure With Reduced Ejection Fraction and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2021, 10, e018631.	1.6	4
16	Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 319-329.	10.6	594
17	A Bibliometric Analysis of Peer-Reviewed Journal Publications of Pharmacy Practice Department Chairs. <i>American Journal of Pharmaceutical Education</i> , 2021, 85, 8481.	0.7	3
18	An ounce of prevention is worth a pound of cure: considerations for pharmacists delivering the National Diabetes Prevention Program. <i>Pharmacy Practice</i> , 2021, 19, 2426.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Pharmacist-administered long-acting injectable PCSK9 service: A solution to improve patient access and adherence. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e83-e85.	0.7	4
20	Time of Eating and Cardiorespiratory Fitness in Patients with Heart Failure With Preserved Ejection Fraction and Obesity. <i>Current Developments in Nutrition</i> , 2021, 5, 465.	0.1	0
21	Time of eating and cardiorespiratory fitness in patients with heart failure with preserved ejection fraction and obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2471-2473.	1.1	4
22	Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease. <i>Pharmacotherapy</i> , 2021, , .	1.2	10
23	Effect of Canagliflozin Compared With Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: A Post-Hoc Analysis of the CANA-HF Study. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 78, 407-410.	0.8	0
24	Effect of a Physician/Pharmacist Collaborative Care Model on Time in Target Range for Systolic Blood Pressure: Post Hoc Analysis of the CAPTION Trial. <i>Hypertension</i> , 2021, 78, 966-972.	1.3	8
25	Sex and Age Differences in Ambulatory Blood Pressure Monitoring Tolerability. <i>American Journal of Hypertension</i> , 2021, 34, 335-338.	1.0	4
26	Meta-analysis of clinical outcomes of PCSK9 modulators in patients with established ASCVD. <i>Pharmacotherapy</i> , 2021, 41, 1009-1023.	1.2	26
27	Factors Associated with Antihypertensive Monotherapy Among US Adults with Treated Hypertension and Uncontrolled Blood Pressure Overall and by Race/Ethnicity, NHANES 2013-2018. <i>American Heart Journal</i> , 2021, , .	1.2	2
28	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
29	The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1680-1690.	0.5	1
30	Characterization of pharmacy practice research centers across the United States. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 230-237.	1.5	3
31	Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. <i>Journal of Pharmacy Practice</i> , 2020, 33, 882-894.	0.5	4
32	Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 10-18.	2.4	98
33	Short-term impact of Altmetric Attention Scores on citation counts in selected major pharmacy journals. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 10-14.	0.5	11
34	Impaired Delivery of Cholesterol Effluxed From Macrophages to Hepatocytes by Serum From CKD Patients May Underlie Increased Cardiovascular Disease Risk. <i>Kidney International Reports</i> , 2020, 5, 199-210.	0.4	7
35	Impact of a pharmacist-physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 404-409.	0.5	6
36	Sacubitril-Valsartan for the Treatment of Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 105-107.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Inflammation and Hypertension. Hypertension, 2020, 75, 297-298.	1.3	15
38	Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis. Current Atherosclerosis Reports, 2020, 22, 45.	2.0	19
39	Development and feasibility of a community pharmacy-driven 24-hour ambulatory blood pressure monitoring service. Journal of the American Pharmacists Association: JAPhA, 2020, 60, e332-e340.	0.7	4
40	Primary healthcare policy and vision for community pharmacy and pharmacists in the United States. Pharmacy Practice, 2020, 18, 2160.	0.8	16
41	The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA-HF study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3335.	1.7	27
42	Challenges in pharmacotherapy for older adults: a framework for pharmacogenomics implementation. Pharmacogenomics, 2020, 21, 627-635.	0.6	8
43	PCSK9 Inhibitors in Secondary Prevention—An Opportunity for Personalized Therapy. Journal of Cardiovascular Pharmacology, 2020, 75, 410-420.	0.8	11
44	Effect of pharmacist interventions on reducing low-density lipoprotein cholesterol (LDL-C) levels: A systematic review and meta-analysis. Journal of Clinical Lipidology, 2020, 14, 282-292.e4.	0.6	11
45	Select Drug-Drug Interactions With Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2020, 75, 1341-1350.	1.2	87
46	Pharmacists' role in hypertension management: a review of key randomized controlled trials. Journal of Human Hypertension, 2020, 34, 487-494.	1.0	18
47	Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American Heart Association, 2020, 9, e014941.	1.6	150
48	Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	14
49	Screening, identification, and management of prediabetes to reduce cardiovascular risk: A missed opportunity?. Diabetes/Metabolism Research and Reviews, 2020, 36, e3316.	1.7	3
50	Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk. American Journal of Medicine, 2020, 133, 802-804.	0.6	4
51	Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). Journal of Cardiovascular Pharmacology, 2020, 75, 359-367.	0.8	53
52	Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis. Minerva Cardioangiologica, 2020, 68, 47-50.	1.2	2
53	Measuring research impact in the 21st century: are alternative metrics the answer?. Minerva Cardioangiologica, 2020, 68, 279-281.	1.2	3
54	Time restricted feeding: old tools, new packaging?. Minerva Cardioangiologica, 2020, 68, 539-541.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Introducing Emerging Concepts in Pharmacotherapeutics. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 372-373.	0.8	0
56	Mortality reduction with PCSK9 inhibition: A case of cautious optimism. <i>Journal of Clinical Lipidology</i> , 2019, 13, 712-713.	0.6	0
57	Medicare reimbursement policy for ambulatory blood pressure monitoring: A qualitative analysis of public comments to the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1803-1809.	1.0	6
58	Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity and HFpEF. <i>JACC Basic To Translational Science</i> , 2019, 4, 563-565.	1.9	28
59	Therapeutic Inertia in Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1728-1731.	1.2	50
60	Practice Forum: A new section led by the Center for Pharmacy Practice Innovation at Virginia Commonwealth University School of Pharmacy. <i>Pharmacy Practice</i> , 2019, 17, 1495.	0.8	0
61	Provider status: What does it mean?. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 87-87.	0.5	0
62	Omega-3 Red Blood Cell Content Is Associated with Fat Mass Index and Leptin in Subjects with Obesity and Heart Failure with Preserved Ejection Fraction (P21-001-19). <i>Current Developments in Nutrition</i> , 2019, 3, nzz041.P21-001-19.	0.1	0
63	The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2019, 18, 64.	2.7	32
64	Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 525-537.	0.6	45
65	To tweet or not to tweet? A primer on social media for pharmacists. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 554-562.	0.5	8
66	Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT2 inhibitors and GLP1 receptor agonists. <i>Journal of Internal Medicine</i> , 2019, 286, 16-31.	2.7	24
67	Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease. <i>Current Atherosclerosis Reports</i> , 2019, 21, 16.	2.0	16
68	Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series. <i>Pharmacy Practice</i> , 2019, 17, 1588.	0.8	12
69	A Prescription for Prescribing: Ensuring Continued Pharmacist Preparedness. <i>Annals of Pharmacotherapy</i> , 2018, 52, 697-699.	0.9	5
70	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1499-1502.	2.2	26
71	Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1499-1502.	2.2	36
72	Evolving Role of Non-statin Therapy for the Management of Dyslipidemia and Cardiovascular Risk Reduction: Past, Present, and Future. <i>Pharmacotherapy</i> , 2018, 38, 164-171.	1.2	7

#	ARTICLE	IF	CITATIONS
73	Treatment of Hypertension to Prevent and Treat Heart Failure in Diabetic Patients Should Include Sodium Glucose Co-Transporter 2 Inhibitors. <i>JACC: Heart Failure</i> , 2018, 6, 85.	1.9	1
74	Clinical pharmacist understanding of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. <i>Journal of Clinical Lipidology</i> , 2018, 12, 367-374.e3.	0.6	11
75	Pharmacist-physician collaborative care model and time to goal blood pressure in the uninsured population. <i>Journal of Clinical Hypertension</i> , 2018, 20, 88-95.	1.0	24
76	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1629-1647.	1.4	31
77	Evaluation of Antidepressant use in Patients with Heart Failure with Preserved Ejection Fraction Enrolled in the America's Subgroup of the TOPCAT trial. <i>Journal of Cardiac Failure</i> , 2018, 24, S60-S61.	0.7	0
78	IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005036.	1.6	129
79	The 2017 American College of Cardiology/American Heart Association hypertension guideline and opportunities for community pharmacists. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 382-386.	0.7	8
80	Recent Developments in the Role of Coenzyme Q10 for Coronary Heart Disease: a Systematic Review. <i>Current Atherosclerosis Reports</i> , 2018, 20, 29.	2.0	24
81	Response to Comment on Buckley et al. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. <i>Diabetes Care</i> 2017;40:1733-1738. <i>Diabetes Care</i> , 2018, 41, e86-e87.	4.3	2
82	A Trial of Blood-Pressure Reduction in Black Barbershops. <i>New England Journal of Medicine</i> , 2018, 379, 199-201.	13.9	7
83	Additive manufacturing of pharmaceuticals for precision medicine applications: A review of the promises and perils in implementation. <i>Additive Manufacturing</i> , 2018, 23, 319-328.	1.7	36
84	Selecting appropriate weight loss pharmacotherapies in older adults to reduce cardiovascular risk. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1399-1402.	0.9	3
85	Identifying Core Content for Electrocardiogram Instruction in Doctor of Pharmacy Curricula. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 7009.	0.7	2
86	A Modified Approach to Setting Curriculum Boundaries in Pharmacy School. <i>American Journal of Pharmaceutical Education</i> , 2018, 82, 7010.	0.7	9
87	Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	131
88	Pharmacologic approaches for the management of patients with moderately elevated triglycerides (150-499 mg/dL). <i>Journal of Clinical Lipidology</i> , 2017, 11, 872-879.	0.6	9
89	EARLY DIASTOLIC MITRAL ANNULAR VELOCITY AT PEAK EXERCISE DETERMINES PEAK AEROBIC EXERCISE CAPACITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 889.	1.2	0
90	COMPARISON OF A PHARMACIST-PHYSICIAN COLLABORATIVE CARE MODEL TO STANDARD CARE ON THE TIME TO REACH GOAL BLOOD PRESSURE FOR PATIENTS PRESENTING WITH URGENT HYPERTENSION. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1837.	1.2	1

#	ARTICLE	IF	CITATIONS
91	MANAGEMENT OF OBESITY IN PATIENTS WITH DIASTOLIC DYSFUNCTION. Journal of the American College of Cardiology, 2017, 69, 2106.	1.2	0
92	COMPARISON OF A PHARMACIST-PHYSICIAN COLLABORATIVE CARE MODEL TO STANDARD CARE ON THE TIME TO REACH GOAL BLOOD PRESSURE FOR PATIENTS WITH HYPERTENSION. Journal of the American College of Cardiology, 2017, 69, 2566.	1.2	0
93	Dietary Fat, Sugar Consumption, and Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2017, 2, 513-525.	1.9	51
94	Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions. Current Atherosclerosis Reports, 2017, 19, 46.	2.0	11
95	Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. Diabetes Care, 2017, 40, 1733-1738.	4.3	98
96	Pharmacists as Integral Members of the Cardiovascular Team. JAMA Cardiology, 2017, 2, 1279.	3.0	2
97	Medication Reconciliation vs Medication Review. JAMA - Journal of the American Medical Association, 2017, 318, 965.	3.8	6
98	Practice Patterns for Addressing LDL-Cholesterol Levels Below 40 in Patients Receiving Statin Therapy. Journal of Clinical Lipidology, 2017, 11, 835.	0.6	0
99	Impaired myocardial relaxation with exercise determines peak aerobic exercise capacity in heart failure with preserved ejection fraction. ESC Heart Failure, 2017, 4, 351-355.	1.4	18
100	Interleukin-1 Blockade in Recently Decompensated Systolic Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	171
101	Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up. Drug Design, Development and Therapy, 2017, Volume 11, 2121-2129.	2.0	10
102	Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review. Pharmacy Practice, 2017, 15, 1134-1134.	0.8	44
103	Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (Dâ€‹HART2). Clinical Cardiology, 2017, 40, 626-632.	0.7	56
104	Best Practice for Switching Stable Warfarin Patients. , 2017, , 93-99.		0
105	Significance of P-glycoprotein (P-gp) Drug-Drug Interactions. , 2017, , 201-205.		0
106	Interleukin-1 Blockade in Acute Decompensated Heart Failure. Journal of Cardiovascular Pharmacology, 2016, 67, 544-551.	0.8	98
107	Effectiveness of Pharmacist-Led Amiodarone Monitoring Services on Improving Adherence to Amiodarone Monitoring Recommendations: A Systematic Review. Pharmacotherapy, 2016, 36, 230-236.	1.2	19
108	A review of PCSK9 inhibition and its effects beyond LDL receptors. Journal of Clinical Lipidology, 2016, 10, 1073-1080.	0.6	39

#	ARTICLE	IF	CITATIONS
109	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2487-2488.	1.2	56
110	Letter by Dixon et al Regarding Article, "Watching Television and Risk of Mortality From Pulmonary Embolism Among Japanese Men and Women: The JACC Study (Japan Collaborative Cohort)" <i>Circulation</i> , 2016, 134, e499-e500.	1.6	1
111	Effectiveness of a Pharmacist-Physician Team-Based Collaboration to Improve Long-Term Blood Pressure Control at an Inner-City Safety-Net Clinic. <i>Pharmacotherapy</i> , 2016, 36, 342-347.	1.2	34
112	Usefulness of C-Reactive Protein Plasma Levels to Predict Exercise Intolerance in Patients With Chronic Systolic Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 116-120.	0.7	21
113	Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. <i>Journal of Blood Medicine</i> , 2015, 6, 177.	0.7	2
114	Potassium levels in acute myocardial infarction: definitely worth paying attention to. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 252-253.	1.4	7
115	Current Drug Treatment of Hyperlipidemia in Older Adults. <i>Drugs and Aging</i> , 2015, 32, 127-138.	1.3	10
116	Collaborative Drug Therapy Management and Comprehensive Medication Management—2015. <i>Pharmacotherapy</i> , 2015, 35, e39-50.	1.2	137
117	The CardioMetabolic Health Alliance. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1050-1067.	1.2	211
118	Pharmacologic and Surgical Interventions to Improve Functional Capacity in Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 117-124.	1.0	8
119	Lomitapide and Mipomersen. <i>Journal of Cardiovascular Nursing</i> , 2014, 29, E7-E12.	0.6	14
120	Considerations for Dofetilide Use in the Elderly. <i>The Consultant Pharmacist</i> , 2014, 29, 270-274.	0.4	4
121	Short-term outcomes of an employer-sponsored diabetes management program at an ambulatory care pharmacy clinic. <i>American Journal of Health-System Pharmacy</i> , 2012, 69, 69-73.	0.5	13
122	Evaluation of a pharmacist-managed lipid clinic that uses point-of-care lipid testing. <i>Journal of Clinical Lipidology</i> , 2010, 4, 120-125.	0.6	12
123	Interaction Between Gemfibrozil and Warfarin: Case Report and Review of the Literature. <i>Pharmacotherapy</i> , 2009, 29, 744-748.	1.2	16
124	Safety of Enoxaparin Bridge Therapy in Patients with Mechanical Heart Valves. <i>Annals of Pharmacotherapy</i> , 2008, 42, 143-144.	0.9	2
125	Interprofessional Team-Based Learning Module: Anticoagulation. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 0, , .	0.5	0
126	Interprofessional Education Team-Based Learning Series: Obesity Module. <i>MedEdPORTAL: the Journal of Teaching and Learning Resources</i> , 0, , .	0.5	3